TBPH

Theravance Biopharma Inc.

Price

$16.99

return (12m)

26.32%

p/e

16.38

p/bv

3.04

DIVIDEND YIELD

0.00%

TBPH price

Theravance Biopharma

If you had invested

exposure

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Return on Investment TBPH

1 month

3 months

1 year

2 years

5 years

10 years

return

1 month

0.74%

3 months

3.98%

1 year

26.32%

2 years

102.74%

5 years

20.93%

10 years

0.00%

Asset Comparator

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Fundamentals TBPH

Valuation

P/E

16.38

Sector -2.19

Industry 1.21

P/BV

3.04

Sector 2.22

Industry 2.11

P/Revenue (PSR)

8.45

Sector 2.01

Industry 0.78

EV/EBITDA

-115.09

Sector -17.81

Industry -25.30

EV/EBIT

-103.08

Sector -26.72

Industry -18.04

P/EBITDA

14.16

Sector 0.36

Industry 0.18

P/EBIT

14.67

Sector -3.34

Industry 1.26

P/Total Assets

1.88

Sector 1.23

Industry 0.86

P/Net Current Assets

3.73

Sector -27.35

Industry -12.37

P/Working Capital

2.28

Sector -4.54

Industry -49.48

EPS

1.03

Sector -0.87

Industry -0.55

BVPS

5.57

Sector 3.80

Industry 5.36

Efficiency

Gross Margin

100.00%

Sector 43.36%

Industry 31.53%

EBITDA Margin

-20.69%

Sector -323.65%

Industry -73.39%

EBIT Margin

-23.11%

Sector -194.57%

Industry -11.94%

Operating Margin

9.15%

Sector -24.37%

Industry -9.87%

Net Profit Margins

51.59%

Sector -28.88%

Industry -19.76%

Asset Turnover

0.04

Sector 0.12

Industry 0.22

Profitability

ROE

18.57%

Sector -33.82%

Industry -37.56%

ROA

11.45%

Sector -29.63%

Industry -17.56%

ROIC

11.40%

Sector -431.16%

Industry -111.59%

Dividends

Dividend yield

0.00%

Sector -

Industry -

Payout

0.00%

Sector -

Industry -

Debt

Current Ratio

13.54

Sector 1.84

Industry 1.14

Net Debt / EBITDA

90.36

Sector -1.47

Industry -31.86

Net Debt / EBIT

80.93

Sector -1.32

Industry 2.06

Net Debt / Equity

-1.34

Sector -0.35

Industry 0.14

Gross Debt / Equity

0.00

Sector 0.14

Industry 0.51

Equity/Assets

0.62

Sector 0.42

Industry 0.25

Liabilities/Assets

0.38

Sector 0.46

Industry 0.46

Growth

5Y Revenue CAGR

13.53%

Sector -

Industry -

5Y Earnings CAGR

0.00%

Sector -

Industry -

FAIR VALUE OF Theravance Biopharma ACCORDING TO BENJAMIN GRAHAM

Graham's Fair Value

The Fair Value formula was created by Benjamin Graham to identify stocks with appreciation potential or that are being traded for less than they are worth. Graham was one of the greatest investors in history and Warren Buffett’s mentor.

Current price

$16.99

Fair Value

$11.36

Upside Return potential.

-33.13%

See Graham's ranking

Because it considers equity value in its calculation, this formula may not work well for technology companies.

This is not a buy/sell recommendation; the fair value calculation takes into account only the formula created by Benjamin Graham, published in the book The Intelligent Investor.

Fundamentals TBPH

DRAG THE FRAME TO SEE MORE DATA

Assets	Price (US$)	Return 12m	DY	P/E	P/BV	ROE	Net Profit Margins
TBPH Theravance Biopharma Inc.	$16.99	24.83%	0.00%	16.38	3.04	18.57%	51.59%
LLY Eli Lilly and Compay	$1,280.34	83.05%	0.54%	39.62	31.24	78.84%	33.53%
ISRG Intuitive Surgical Inc.	$397.72	-17.36%	0.00%	45.09	7.73	17.15%	28.45%
SNY Sanofi	$45.83	-4.42%	4.04%	7.10	1.31	18.43%	13.81%
NVS Novartis AG	$160.31	31.78%	2.05%	22.57	6.87	30.41%	22.50%
TMO Thermo Fisher Scientific Inc.	$613.54	26.39%	0.30%	31.58	4.17	13.19%	15.04%
ABT Abbott Laboratories	$114.43	-11.62%	2.33%	33.60	3.57	10.61%	11.65%
MDT Medtronic PLC	$94.13	4.71%	3.10%	24.50	2.35	9.59%	13.20%
GSK GlaxoSmithKline PLC	$52.88	41.51%	3.59%	15.15	4.28	28.24%	14.54%
CVS CVS Health Corporation	$93.65	37.68%	2.73%	25.48	1.56	6.12%	1.18%
BSX Boston Scientific Corp.	$52.01	-49.87%	0.00%	18.98	0.00	-%	19.57%
TMDX TransMedics Group Inc.	$93.97	-25.21%	0.00%	20.36	5.96	29.28%	22.69%
IDXX IDEXX Laboratories Inc.	$562.20	-11.86%	0.00%	38.32	27.08	70.67%	25.03%
RMD ResMed Inc.	$230.65	-18.34%	1.07%	21.40	4.95	23.13%	26.94%
DHR Danaher Corporation	$211.50	0.79%	0.71%	35.81	2.73	7.61%	15.95%
HCA HCA Healthcare Inc.	$407.05	4.09%	0.74%	13.12	-27.97	-213.15%	8.77%
COHR Coherent Inc.	$287.47	217.68%	0.00%	79.32	5.68	7.16%	11.31%
PHG Koninklijke Philips NV	$27.62	4.58%	3.70%	20.19	1.98	9.80%	6.30%
SYK Stryker Corp.	$339.98	-9.77%	1.02%	34.97	5.44	15.55%	14.43%
INMD InMode Ltd.	$15.04	5.14%	0.00%	11.54	1.42	12.32%	20.69%

Stock vs Indice Comparison Tool

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

TBPH Historical Dividends

current DY: 0.00%

5-year average DY: 0.00%

no dividend paid in the period.

ABOUT Theravance Biopharma

Theravance Biopharma Inc.

Average Investor10 user rating

4.0 (2 people)

United States

13 years

Founded: 2013

2014

Time since IPO - 12 years

359

Employees

Theravance Biopharma Inc. (United States) is listed on the Nasdaq and has a market capitalization of $881.40 million, with shareholders equity totaling $289.70 million.

The company employs approximately 359 people and operates in the Health sector, within the Pharmaceutical Products industry.

Over the past 12 months, Theravance Biopharma Inc. reported $104.31 million in revenue, generating net income of $53.81 million.

Key financial metrics include a P/E ratio of 16.38, a price-to-book (P/B) ratio of 3.04, and a trailing twelve-month dividend yield of 0.00%.

The company trades under the ticker TBPH.

Market cap

$881.40 million

Net worth

$289.70 million

$289,700,000.00

Assets

$469.77 million

$469,770,000.00

Total Shares Outstanding

52.00 million

52,000,000

Average Daily Trading Volume

$705.10 Thousand

$705,101.00

Sector

Health

Industry

Pharmaceutical Products

TBPH

TBPH revenue and profits

Financial Results TBPH

DRAG THE FRAME TO SEE MORE DATA

TBPH cash flow

DRAG THE FRAME TO SEE MORE DATA

Discover more assets

CVS - CVS Health

$93.65 36,41% (12M)

P/E

25.48

2.73%

ROE

6.12%

P/BV

1.56

CI - Cigna

$277.45 --6,37% (12M)

P/E

10.82

2.19%

ROE

16.04%

P/BV

1.74

CNC - Centene

$64.69 120,03% (12M)

P/E

-6.48

0.00%

ROE

-22.51%

P/BV

1.46

HUM - Humana

$378.02 32,24% (12M)

P/E

36.20

0.92%

ROE

6.63%

P/BV

2.40

SNY - Sanofi

$45.83 --5,73% (12M)

P/E

7.10

4.04%

ROE

18.43%

P/BV

1.31

LLY - Eli Lilly

$1,280.34 81,92% (12M)

P/E

39.62

0.54%

ROE

78.84%

P/BV

31.24

HCA - HCA Healthcare

$407.05 --0,11% (12M)

P/E

13.12

0.74%

ROE

-213.15%

P/BV

-27.97

NVS - Novartis

$160.31 28,43% (12M)

P/E

22.57

2.05%

ROE

30.41%

P/BV

6.87